Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists (PROMPT-MRA)

The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescription of this guideline-recommended therapy. The …

  • 0 views
  • 23 Mar, 2022
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require …

  • 193 views
  • 26 Jan, 2021
  • 98 locations
Calcium Channel Blockade in Primary Aldosteronism

Primary aldosteronism is a common cause of hypertension. Recent evidence suggests that many patients with bilateral idiopathic hyperaldosteronism harbor gain-of-function somatic mutations in zona glomerulosa calcium channels that results in aldosterone production. This finding raises the possibility that calcium channel antagonists may be a targeted therapy to reduce aldosterone production …

calcium channel
amlodipine
aldosterone
hypertension
adrenal venous sampling
  • 0 views
  • 16 Dec, 2021
  • 1 location
Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy (MRA-ACE)

NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR. Because of combination MRA and RAAS therapy significantly increases the risk for clinically significant hyperkalemia, we also …

proteinuria
angiotensin
hypertension
diabetes
antihypertensive drugs
  • 34 views
  • 23 Mar, 2022
  • 2 locations
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

bevacizumab versus folfiri plus aflibercept in second-line treatment of mRAS mCRC. Furthermore, the serum levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A and C

folfiri regimen
growth factor
EGFR
aflibercept
vegf
  • 0 views
  • 24 Jan, 2021
  • 1 location
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels (SPLENDID)

China National Heart Failure Registration Study (CN-HF) is a nationwide, hospital-based, multicentre, prospective registry study sponsored by Ministry of Science and Technology of the People's Republic of China. It is aimed to understand the etiology, clinical features and treatments of in-hospital HF patients in China [3]. At present, there are …

potassium
heart failure
  • 0 views
  • 25 May, 2022
  • 1 location
Comparison of Magnetic Resonance Coronary Angiography (MRCA) With Coronary Computed Tomography Angiography (CTA)

Magnetic resonance coronary angiography (MRCA) has its advantage in its ability to assess the coronary artery morphology without radiation or contrast media. The clinical application of MRCA is still challenging mainly because of technical limitations such as: its time-consuming image acquisition, inconsistent image quality, and low spatial resolution. Optimization of …

  • 0 views
  • 24 Apr, 2022
  • 1 location